echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Renfu Medicine HW021199 tablets are approved for clinical use in the treatment of idiopathic pulmonary fibrosis

    Renfu Medicine HW021199 tablets are approved for clinical use in the treatment of idiopathic pulmonary fibrosis

    • Last Update: 2021-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 30, Renfu Medicine issued an announcement stating that recently, its subsidiary Hubei Biomedical Industry Technology Research Institute Co.
    , Ltd.
    (referred to as the "Research Institute Co.
    , Ltd.
    ", the company holds 50.
    24% of its shares), Wuhan Renfu Kangyao Industry Co.
    , Ltd.
    (referred to as "Ren Fuli Kang", the company holds 67.
    33% of its equity, and according to the forward repurchase agreement of the capital increase agreement, the company holds 100% of its equity) received the HW021199 film approved and issued by the State Drug Administration "Notice of Approval of Drug Clinical Trials"
    .

    HW021199 tablets are suitable for the treatment of idiopathic pulmonary fibrosis
    .


    At present, there is no drug with the same target on the market globally.


    According to IQVIA statistics, the global sales of nintedanib and pirfenidone in 2019 were approximately US$980 million and US$747 million, respectively
    .


    Research Institute Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.